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Four healthy volunteers were infected with 50 Necator 
americanus infective larvae (L3) in a controlled human hook-
worm infection trial and followed for 52 weeks. The kinetics of 
fecal egg counts in volunteers was assessed with Bayesian mul-
tilevel analysis, which revealed an increase between weeks 7 and 
13, followed by an egg density plateau of about 1000 eggs/g of 
feces. Variation in egg counts was minimal between same-day 
measurements but varied considerably between days, particu-
larly during the plateau phase. These analyses pave the way for 
the controlled human hookworm model to accelerate drug and 
vaccine efficacy studies.
Keywords. hookworm; controlled human infection; 
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Hookworms affect almost 500 million people worldwide, pre-
dominantly in developing countries. Pathology is caused by 
blood and protein loss at the site of intestinal attachment, par-
ticularly in individuals with low iron and protein stores, such as 
children or women of childbearing age [1].
Currently, hookworm elimination rates fall behind those 
of other soil-transmitted helminths [2], especially in high-
prevalence areas. High reinfection rates and the exclusion of adult 
populations in mass drug administration programs targeting 
school-age children hamper the goal to interrupt transmission 
[3]. A vaccine would be a crucial tool to aid current hookworm-
control programs. Two vaccine candidates are in phase 1 clinical 
testing in volunteers in Gabon, Brazil, and the United States [4]. 
However, testing of efficacy in field trials is a large-scale, costly 
endeavor, slowing down vaccine development [5].
Efficacy in vaccine trials can be estimated using a binary out-
come, but quantitative measurements are preferable. This relies 
on fecal egg counting, a widely used way of measuring infec-
tion intensity in humans [6]. However, in field settings, fecal egg 
counts are highly variable, owing to differences in the host im-
mune response, dietary intake, episodes of diarrhea, transport 
and storage of samples, laboratory conditions, availability of 
highly trained technicians, and other technical factors, thereby 
limiting the power of field trials to detect vaccine efficacy [7].
The development and clinical implementation of hook-
worm vaccines could be accelerated by the implementation 
of controlled human hookworm infection (CHHI) models 
within the product pipeline, as has been shown for malaria 
and influenza vaccines [8]. The CHHI model has been used for 
immunomodulatory purposes, such as investigations involving 
celiac disease [9], using doses of 10 or 20 L3 larvae. A recent 
trial by Diemert et al, aimed at developing a model for vaccine 
testing, showed that infection with 50 L3 larvae resulted in infec-
tion in 9 of 10 volunteers and was well tolerated [10]. However, 
egg counts were lower than typically seen in field studies [11]. 
To obtain a better comparison to the field, higher egg counts 
would be preferable. Furthermore, an improved understanding 
of the kinetics and variability of egg excretion over a prolonged 
period could help dissect factors underlying the variability in 
egg output. As a result, the most-reliable time points with the 
lowest variability can be identified, and the power of vaccine 
trials can be improved.
In this study, we investigated the kinetics of egg excretion over 
an extended period in a CHHI model, using an infective dose 
of 50 L3 larvae. Patterns and variability in egg excretion were 
quantified using Bayesian multilevel analysis. Our findings can 
be used to create an improved CHHI model that could be of great 
value in accelerating the testing of novel vaccines or medicine.
METHOD
Necator americanus L3 larvae were produced according to the 
principles of good manufacturing practice (GMP) but not in 
a GMP-licensed cleanroom. Material for culture was obtained 
from a chronically infected donor from James Cook University 
[9] who was carrying a N. americanus strain originating from 
Madang, Papua New Guinea, that was previously maintained 
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at the University of Nottingham. The donor was confirmed 
to be negative for blood-borne infections (ie, human immu-
nodeficiency virus [HIV], hepatitis B virus, and hepatitis 
C virus infections), and a fecal specimen was screened for 
viral, bacterial, and parasitic pathogens. The fecal specimen 
containing N.  americanus eggs was cultured for 7  days, after 
which larvae were harvested [12]. Water containing the infec-
tious N. americanus L3 larvae was cultured for pathogenic bac-
teria, and the identity of the infectious larvae was confirmed 
by polymerase chain reaction (PCR) analysis. Viability of the 
larvae, as measured by a visual count of moving larvae, varied 
between 88% and 92% for different batches. Larvae were used 
for infection within 10 days of harvesting. A detailed produc-
tion process of the larvae is described in the Supplementary 
Materials.
Healthy male and female volunteers aged 18–45 years were 
recruited in April 2017 and provided written informed con-
sent. Exclusion criteria were a body mass index (calculated 
as the weight in kilograms divided by the height in meters 
squared) of <18.0 or >30.0; iron deficiency anemia; positive 
results of fecal PCR analysis for N. americanus, Ancylostoma 
duodenale hookworm, or Strongyloides organisms; positive 
results of serologic analysis for hepatitis B virus, hepatitis C 
virus, or human immunodeficiency virus; contraindications 
for the use of albendazole; planned travel to a hookworm-
endemic area; incomplete understanding of the study 
procedures; or any medical condition that could interfere with 
participation in the trial.
For the preparation of each dose, individual motile larvae 
were selected from the prior released batch to ensure the highest 
possible viability. Every dose of 50 N. americanus L3 larvae was 
dispensed within 15 minutes after preparation onto 4 gauzes, 
with 2 containing doses of 10 larvae and 2 containing doses of 
15 larvae, which were applied to the dorsal side of volunteers’ 
upper arms and calves, respectively, for 60 minutes.
Adverse events were recorded and total eosinophil count 
and hemoglobin level were measured weekly during the first 
12 weeks and 6 and 12 months after infection. For every ad-
verse event, the time and date of onset and end, severity, and 
cause were recorded. Adverse events could be unrelated or 
unlikely, possibly, probably, or definitely related; the latter 3 
categories are regarded as “related” in dichotomous analyses. 
Relatedness was assessed by the clinical trial physician. Fecal 
samples were collected weekly from week 5 after infection 
onward and checked for N.  americanus eggs by the Kato-
Katz technique. Slides with 25  mg of stool were prepared 
from homogenized stool specimens [12]. Two slides per fecal 
sample were read by 2 different slide readers. After 12 weeks 
of follow-up, volunteers were asked to return at irregular 
intervals (not a prespecified pattern) for on-demand fecal 
specimen donation during the course of a year, depending 
on the need for samples at the laboratory. These on-demand 
donations were used for additional egg counts and further 
culturing of the larvae.
Variability in egg counts between and within individuals 
over time was analyzed using Bayesian multilevel analysis. We 
assumed that egg counts initially increase and then stabilize 
over time, according to a scaled cumulative normal distribu-
tion function. We considered the following 3 levels to describe 
the variation of egg counts. First, the level at which egg counts 
stabilize was allowed to vary between individuals, assuming a 
log-normal distribution. Second, variation in daily averages 
was assumed to follow a gamma distribution. Last, the sam-
pling error among repeated egg counts on the same day in the 
same individual was assumed to follow a Poisson distribution 
(in which variance equals the mean value) or a negative bino-
mial distribution (in which variance is greater than the mean 
value). Parameter values were estimated using the package rstan 
(version 2.16.2) [13] in R (version 3.4.3).
This trial was approved by the local institutional review 
board (protocol P17.001) and is registered at ClinicalTrials.gov 
(NCT03126552).
RESULTS
Four volunteers were included in the study, of whom 3 were 
women and 1 was a man, (age range, 19–23  years). Infection 
with 50 N. americanus L3 larvae was well tolerated and resulted 
in patent hookworm infection in all four volunteers.
All volunteers reported rash at the sites of infection (Figure 
1A), lasting for 11, 22, 31, and 32 days, and itching, lasting for 
1–2  days. There was no difference in the intensity of rash or 
itching between the infection sites on arms and those on legs. 
The most common adverse event was abdominal pain, with 11 
episodes among the volunteers; 9 were classified as mild, 1 was 
classified as moderate, and 1 was classified as severe and lasted 
5 hours. Other abdominal events were nausea (in 2 volunteers) 
and flatulence (in 1 volunteer), all of which were mild (Figure 
1B); these events started at week 3, increased in frequency until 
week 6, and then decreased in frequency through week 9, after 
which no abdominal complaints were reported. No volunteers 
reported related adverse events after week 12 (Supplementary 
Materials).
No volunteers developed anemia. Eosinophil counts 
increased steeply in all volunteers after infection, peaking at 
week 6 (range, 2.02 × 109–6.96 × 109 eosinophils/L). Eosinophil 
counts declined afterward but remained slightly elevated at week 
12 in all volunteers (range, 0.82 × 109–1.77 × 109 eosinophils/L). 
Counts were still elevated in 2 volunteers at week 52 (1.18 × 109 
and 0.72 × 109 eosinophils/L), with one having had an elevated 
count at baseline (0.74  ×  109 and 0.34  ×  109 eosinophils/L, 
respectively).
Kato-Katz slides were all negative for eggs at weeks 5 and 6 
after infection and became positive for eggs in 1 volunteer at 
week 7 after infection. At week 9, all volunteers were excreting 
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eggs, based on analysis of Kato-Katz slides. The median egg den-
sity at the end of the first follow-up period (ie, at week 12) was 
560 eggs/g of stool (range, 160–1680 eggs/g of stool). After the 
initial follow-up, volunteers donated fecal specimens at irreg-
ular intervals, enabling data collection up to week 52.
Bayesian multilevel analysis showed that, by week 10, egg 
counts had risen to about half the maximum level and reached 
their maximum level around week 13 (Figure 2A). Thereafter, 
egg excretion remained relatively stable, with considerable var-
iation among daily averages within individuals. The estimated 
population-level plateau in the egg count was 25.8 eggs/slide, 
corresponding to around 1000 eggs/g of feces. Assumption 
of negative binomial variation instead of Poisson distribution 
among repeated egg counts on the same day did not improve 
the model fit (Figure 2B).
DISCUSSION
This study shows that experimental infection with 50 L3 
N.  americanus larvae divided over 4 application sites is well 
tolerated and leads to patent infection, with eosinophilia and 
fecal egg excretion in all 4 volunteers. Long-term follow-up 
showed that egg counts increased from week 7 to week 13 after 
infection and then reached a stable level. The peak of adverse 
events, primarily abdominal complaints, occurred around 6 
weeks after the infection, coinciding with peak eosinophilia. 
This time point is thought to mark the establishment of the 
larvae in the intestine.
To alleviate dermal symptoms, we divided the infectious 
larval dose over 4 extremities. Although the median duration 
of rash was similar, the intensity of local events was decreased 
as compared to observations by Diemert et al [10]. The levels 
of egg excretion, however, were much higher than in any pre-
vious report [9, 10] and were not accompanied by more severe 
abdominal adverse events [10]. This enhanced infectivity could 
be related to the viability of larvae, which was >88%, and all 
were used within 10 days of harvesting. Alternatively, the appli-
cation of larvae over several sites may have enhanced infectivity. 
The plateaus in egg counts observed in this study are below the 
World Health Organization–defined cutoff for a light infec-
tion (ie, 2000 eggs/g of stool) [6]. Comparable average levels of 
excreted eggs are widely observed in areas of endemicity [14].
Although volunteers with experimental hookworm infec-
tion have undergone long follow-up before [15], this is the first 
study to describe the kinetics of N.  americanus egg excretion 
over a prolonged period in multiple volunteers. We found low 
variability between egg counts on the same day within the same 
individuals, allowing for a Poisson distribution. This is remark-
able because variation in egg counts in field studies is generally 
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Figure 1. Overview of adverse events. A, Representative rash at week 1 after infection. (left: arm, 10 L3 Necator americanus larvae; right: leg, 15 L3 N. americanus larvae). 
B, All reported adverse events considered to be related to the study.
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much higher and can only be described by a negative bino-
mial distribution [7]. It is possible that the highly standardized 
method of slide preparation and feces homogenization in this 
trial and the lack of reinfection reduced the variability in egg 
output. However, more data are needed to further quantify the 
day-to-day variation within and between individuals. Although 
findings of PCR analysis may potentially be less variable, mi-
croscopy findings are still the preferred primary end points in 
phase 2 vaccine or drug trials. Bayesian multilevel analysis is 
helpful to accurately assess the stabilizing levels of egg excre-
tion from 13 weeks onward despite several levels of variability 
and, as such, will provide key information for the future design 
of controlled human hookworm trials testing novel medicines 
or vaccines. Vaccine efficacy can be detected through a lower 
plateau level, a later or slower increase in egg counts, or a com-
bination of these factors. The timing and level of the plateau 
in egg counts could be a reliable end point for clinical trials, 
assuming that follow-up is extended beyond 13 weeks. Despite 
the small sample size, these promising findings add to the ex-
isting arguments for using CHHI models for early vaccine effi-
cacy studies.
In conclusion, we found that controlled human infection 
with 50 L3 N.  americanus larvae was well tolerated, resulting 
in infection of all volunteers and unparalleled high egg counts. 
Although the number of subjects in this study was limited, our 
results show great promise in developing a sustainable human 
hookworm infection model that, aided by Bayesian statistical 
analysis of egg kinetics, could be of great value in accelerating 
clinical testing of novel vaccines and medicines.
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Figure 2. Individual fecal egg counts over time. A, Observed egg counts (dots) versus estimated individual fecal egg density kinetics (solid lines), assuming Poisson varia-
tion among repeated egg counts. Gray bands are 95% Bayesian credible intervals. B, Parameters when assuming negative binomial or Poisson variation. Data are posterior 
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